TF-Al |
|
Vaxjo ID |
264 |
|
Vaccine Adjuvant Name |
TF-Al |
|
Adjuvant VO ID |
VO_0005751
|
|
Description |
TF-Al is a combined adjuvant made by mixing TFPR1 (a novel immune modulator activating TLR2) with Aluminum hydroxide (Alum). It enhances both Th1- and Th2-type immune responses and is designed to improve vaccine efficacy in genetically diverse subjects. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
TFPR1 is a novel adjuvant for protein and peptide antigens,formulating TFPR1 and alum at a certain ratio and compared its adjuvanticity with that of TFPR1 and alum |
|
Structure |
Physical mixture of TFPR1 protein + Alhydrogel® alum Final volume ratio: 1 (alum): 4 (TFPR1): 5 (antigen) |
|
Preparation |
Mix 1 part alum with 4 parts TFPR1 (250 µg/mL) Combine with equal volume of antigen solution Final dose contains 10 µg TFPR1 in 100 µL |
|
Dosage |
OVA: 10 µg per mouse (3 injections, 3-week intervals) HBsAg: 1 µg per mouse (2 injections, 3-week interval) |
|
Function |
we first compared the adjuvanticity of TFPR1 in two commonly used inbred mouse strains, BALB/c and C57BL/6 mice, in vitro and in vivo, and demonstrated that TFPR1 activated TLR2 to exert its immune activity in vivo |
|
Safety |
No adverse effects reported in mice |
| References |
Li et al., 2021: Li Q, Liu Z, Liu Y, Liang C, Shu J, Jin X, Li C, Kou Z. A Combined Adjuvant TF-Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice. Vaccines. 2021; 9(12); . [PubMed: 34960154].
|
